Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $69.8 million.

  • Ani Pharmaceuticals' Accounts Payables rose 1462.47% to $69.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.8 million, marking a year-over-year increase of 1462.47%. This contributed to the annual value of $45.7 million for FY2024, which is 2446.09% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Accounts Payables of $69.8 million as of Q3 2025, which was up 1462.47% from $54.6 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Accounts Payables high stood at $69.8 million for Q3 2025, and its period low was $11.5 million during Q3 2021.
  • In the last 5 years, Ani Pharmaceuticals' Accounts Payables had a median value of $32.7 million in 2023 and averaged $35.4 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 1446.51% in 2021, then skyrocketed by 11299.99% in 2022.
  • Ani Pharmaceuticals' Accounts Payables (Quarter) stood at $23.0 million in 2021, then increased by 27.6% to $29.3 million in 2022, then rose by 25.18% to $36.7 million in 2023, then grew by 24.46% to $45.7 million in 2024, then soared by 52.87% to $69.8 million in 2025.
  • Its Accounts Payables stands at $69.8 million for Q3 2025, versus $54.6 million for Q2 2025 and $53.1 million for Q1 2025.